Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial

Original Article by Deena Beasley and Manas Mishra | Reuters | 17 April 2025

Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.

Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Momentum Group Posts Record Earnings

Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.

Read more...

Sanlam Writes Down AfroCentric to Nil but Won’t Sell

Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.

Read more...

GLP-1 Alone Won’t Solve South Africa’s Diabetes Crisis

GLP-1 medicines alone can’t solve SA’s diabetes crisis, experts warn, urging earlier screening, coordinated care and better food access.

Read more...